With 1.63 million shares changed hands, the volume of the stock remained lighter than its average volume of 17.06 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.61 whereas the lowest price it dropped to was $0.5576. The 52-week range on CLDI shows that it touched its highest point at $3.89 and its lowest point at $0.20 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 1.14.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLDI was up-trending over the past week, with a rise of 7.91%, but this was up by 141.29% over a month. Three-month performance surged to 19.07% while six-month performance fell -21.78%. The stock lost -48.43% in the past year, while it has lost -62.22% so far this year. A look at the trailing 12-month EPS for CLDI yields -1.84 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.16. This implies an EPS growth rate of 79.12% for this year and 25.81% for next year.
Float and Shares Shorts:
At present, 34.52 million CLDI shares are outstanding with a float of 32.31 million shares on hand for trading. On 2025-07-15, short shares totaled 3.47 million, which was 84.0 higher than short shares on 1749772800. In addition to Mr. Andrew C. Jackson as the firm’s Chief Financial Officer, Ms. Wendy Pizarro Campbell Esq. serves as its Chief Legal, Chief Corporate Dev, Chief Diversity & Corp Sec..
Institutional Ownership:
Through their ownership of 0.15853 of CLDI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, CLDI reported revenue of $0.0 and operating income of -$5012000.0. The EBITDA in the recently reported quarter was -$4628000.0 and diluted EPS was -$0.18.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CLDI analysts setting a high price target of 120.0048 and a low target of 120.0048, the average target price over the next 12 months is 120.0048. Based on these targets, CLDI could surge 20239.8% to reach the target high and rise by 20239.8% to reach the target low. Reaching the average price target will result in a growth of 20239.8% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.695 being high and -$3.695 being low. For CLDI, this leads to a yearly average estimate of -$3.695.
